Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type I.

@article{Shugars1997SecretoryLP,
  title={Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type I.},
  author={Diane C. Shugars and Derrick L. Sauls and Jason B Weinberg},
  journal={Oral diseases},
  year={1997},
  volume={3 Suppl 1},
  pages={
          S70-2
        }
}
Saliva contains factors that inhibit infection with the human immunodeficiency virus type 1 (HIV-1) in vitro. One of these factors was recently identified as secretory leukocyte protease inhibitor (SLPI), a salivary protein which blocked HIV-1 infectivity of monocytes and primary T cells at physiologic concentrations (J Clin Invest 1995; 96: 456). Here, we confirm and extend the original report by demonstrating that SLPI protects primary monocytes and peripheral blood mononuclear cells against… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 18 CITATIONS

Similar Papers

Loading similar papers…